secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0000950170-25-072046
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics Q1 net loss $3.7M, cash $2.6M; advances ADC pipeline
-----------------------------------------------------------------------

- Net loss from operations $3.7M in Q1 2025 vs $5.6M in Q1 2024; R&D spend down to $0.8M.
- Cash $2.6M as of March 31, 2025; March 2025 offering netted $6.0M, $4.0M received in April.
- Appointed Mark Kubik as Head of Business Development, Oncology to strengthen ADC expertise.
- Expects to present preclinical data for PH1-payload ADC at a scientific conference in H2 2025.
- Pipeline lead AKTX-101 (Trop2/PH1 ADC) advancing; out-licensing non-core assets for non-dilutive capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017025072046/0000950170-25-072046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017025072046/aktx-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-072046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer